Formulary Search
Search Results : Chronic Obstructive Pulmonary Disease (COPD) (Indacaterol (Onbrez Breezhaler) - Chronic Obstructive Pulmonary Disease (COPD))
Show Icon and Status Keys
- Not Specified
- Not Specified
- Inhaler (dry powder)
LABA monotherapy no longer recommended for asthma or COPD.
Not for initiation in new patients.
- Inhaler (dry powder)
Combination with LABA recommended in COPD.
Prescribe by BRAND
- Inhaler (dry powder)
Prescribe by BRAND
- Inhaler (dry powder)
Fostair NEXThaler 100/6
Prescribe by BRAND
- Inhaler (Metered Dose)
Fostair 100/6, 200/6 not licensed in under 18 years. Not licensed for AIR.
Not for initiation in new patients. Proxor device is much less expensive.
Further information is being sought with regard to Proxor / Fostair bioequivalence. To be reviewed in Jul/Aug 2025.
- Inhaler (Metered Dose)
Proxor 100/6 - NEW device.
Fostair equivalent - Proxor is the most cost-effective ICS/formoterol pMDI. Licensed for MART in adults.
Prescribe by BRAND.
- Inhaler (Metered Dose)
Trimbow 87/5/9 (higher strengths not licensed for COPD)
Prescribe by BRAND
- Inhaler (dry powder)
- Nebules
Specialist recommendation following patient initiation and education on nebuliser therapy.
- Inhaler (dry powder)
DuoResp Spiromax 160/4.5 - second line (Fobumix Easyhaler (budesonide/formoterol) is the more cost-effective option DPI).
Prescribe by BRAND.
- Inhaler (dry powder)
DuoResp Spiromax 320/9 - this strength is not recommended in the Surrey Heartlands COPD guidelines.
- Inhaler (dry powder)
Symbicort Turbohaler 400/12 - second line (Fobumix Easyhaler (budesonide/formoterol) is the more cost-effective option DPI)
Prescribe by BRAND
- Inhaler (dry powder)
- Inhaler (dry powder)
Relvar Ellipta 92/22
- Inhaler (dry powder)
Easyhaler Formoterol
LABA monotherapy no longer recommended for asthma or COPD.
Not for initiation in new patients.
- Inhaler (dry powder)
Oxis Turbohaler
LABA monotherapy no longer recommended for asthma or COPD.
Not for initiation in new patients.
- Inhaler (dry powder)
Second line - low resistance inhaler. With low-resistance devices, patients must inhale faster to generate the power to separate the drug molecules, which may be difficult in patients with poor lung function.
Combination with LABA recommended in COPD.
Prescribe by BRAND
- Inhaler (Metered Dose)
This is the only LAMA/LABA available in an MDI device. Same cost as other LAMA/LABAs
- Inhaler (dry powder)
Second line - low-resistance device so patients must inhale faster to generate the power to separate the drug molecules, which may be difficult in patients with poor lung function.
Prescribe by BRAND
- Inhaler (Metered Dose)
No added benefit in patient's on LAMA.
Not for initiation in new patients.
- Nebules
Specialist recommendation following patient initiation and education on nebuliser therapy, unless for administration as PSD in practice for acute attack.
- Soft mist inhaler
LABA monotherapy no longer recommended for asthma or COPD.
Not for initiation in new patients.
- Inhaler (dry powder)
Cost-effective, low carbon DPI.
Prescribe by BRAND.
- Nebules
Specialist recommendation following patient initiation and education on nebuliser therapy, unless for administration as PSD in practice for acute attack.
- Inhaler (breath actuated Metered Dose)
Second line, as an alternative to Salbutamol Easyhaler, in patients needing a breath actuated inhaler
Second line - for patients needing a breath-actuated device
- Inhaler (Metered Dose)
No dose counter. Lower carbon footprint than Ventolin Evohaler.
Prescribe by BRAND.
- Inhaler (dry powder)
Easyhaler Salbutamol is preferred. Ventolin Accuhaler is a suitable low-carbon alternative DPI.
Not for initiation in new patients.
- Inhaler (dry powder)
Easyhaler Salbutamol is preferred. Ventolin Accuhaler is a suitable low-carbon alternative DPI.
Prescribe by BRAND
- Inhaler (Metered Dose)
No dose counter. Higher carbon footprint than the Salamol MDI.
Not for initiation in new patients.
- Inhaler (Metered Dose)
Serevent Evohaler
LABA monotherapy no longer recommended for asthma or COPD.
Not for initiation in new patients.
- Inhaler (dry powder)
Serevent Accuhaler
LABA monotherapy no longer recommended for asthma or COPD.
Not for initiation in new patients.
- Inhaler (dry powder)
Alternative low carbon DPI (Easyhaler Salbutamol is the more cost-effective treatment option)
Prescribe by BRAND.
- Nebules
Specialist recommendation following patient initiation and education on nebuliser therapy
- Injection
Severe acute asthma
- Inhaler (dry powder)
Safety concerns with device. Combination of LAMA and LABA recommended in COPD.
Not for initiation in new patients.
- Inhaler (dry powder)
Expensive device, no advantage over other LAMAs, and combination with LABA recommended in COPD.
Not for initiation in new patients.
- Soft mist inhaler
Combination with LABA recommended in COPD.
Prescribe by BRAND.
- Soft mist inhaler
- Inhaler (dry powder)
Combination with LABA recommended in COPD.
Prescribe by BRAND.
- Inhaler (dry powder)
- Inhaler (dry powder)
Prescribe by BRAND.
- Inhaler (Metered Dose)
Symbicort 200/6 - only for use if an MDI is needed.
- Nebules
Specialist recommendation following patient initiation and education on nebuliser therapy
- Tablets
- Inhaler (dry powder)
Not recommended in Surrey Heartlands COPD guidelines.
Not for initiation in new patients.
- Inhaler (dry powder)
Not for initiation in new patients.
Not assessed for inclusion on the formulary. Contact pharmacy team for advice on making an application.